加载中
Kringle Pharma, Inc. specializes in the innovation, production, and distribution of hepatocyte growth factor (HGF) protein-based therapeutics aimed at regenerative medicine. The company's cutting-edge HGF solutions are designed to address serious medical conditions including acute spinal cord injury, amyotrophic lateral sclerosis, vocal fold scars, and acute kidney injury. Founded in 2001, Kringle Pharma operates from its base in Ibaraki, Japan.
最新数据
JP¥614
+JP¥2.00 · +0.33%
盘中时间采用JST。市场数据可能有所延迟。
Kringle Pharma, Inc. specializes in the innovation, production, and distribution of hepatocyte growth factor (HGF) protein-based therapeutics aimed at regenerative medicine. The company's cutting-edge HGF solutions are designed to address serious medical conditions including acute spinal cord injury, amyotrophic lateral sclerosis, vocal fold scars, and acute kidney injury. Founded in 2001, Kringle Pharma operates from its base in Ibaraki, Japan.
日内区间
当前JP¥614
52周区间
当前JP¥614
盘中时间采用JST。市场数据可能有所延迟。
Kringle Pharma, Inc. specializes in the innovation, production, and distribution of hepatocyte growth factor (HGF) protein-based therapeutics aimed at regenerative medicine. The company's cutting-edge HGF solutions are designed to address serious medical conditions including acute spinal cord injury, amyotrophic lateral sclerosis, vocal fold scars, and acute kidney injury. Founded in 2001, Kringle Pharma operates from its base in Ibaraki, Japan.
日内区间
当前JP¥614
52周区间
当前JP¥614
盈利能力占已公布营收的百分比。
营收
营业利润
净利润
| 项目（JPY） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 营收 | 7221.5万 JPY | 8003.8万 JPY | 6925万 JPY | 3.92亿 JPY | 2.9亿 JPY |
| 销货成本 | — | — | — | 8841.3万 JPY | 7159.8万 JPY |
| 毛利 | 7221.5万 JPY | — | — | 3.03亿 JPY | 2.18亿 JPY |
| 研究与开发 | 6.81亿 JPY | 6.43亿 JPY | 7.17亿 JPY | 5.33亿 JPY | 3.99亿 JPY |
| 销售、一般及管理费用 | 3亿 JPY | 2.55亿 JPY | 2.41亿 JPY | 1.96亿 JPY | 1.78亿 JPY |
| 营业费用 | 9.82亿 JPY | 8.98亿 JPY | 9.58亿 JPY | 7.3亿 JPY | 5.76亿 JPY |
| 利息收入 | 17.9万 JPY | 18.9万 JPY | 5000 JPY | — | 1000 JPY |
| 营业利润 | −9.09亿 JPY | −8.18亿 JPY | −8.89亿 JPY | −4.26亿 JPY | −3.58亿 JPY |
| 净利润 | −9.16亿 JPY | −7.56亿 JPY | −8.54亿 JPY | −3.32亿 JPY | −3.01亿 JPY |
公司数据更新于 2026年10月17日。
近期已公布业绩
近期已公布业绩
AI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
